Skip to main navigation Skip to search Skip to main content

Corrigendum to ‘Oligometastatic disease in esophagogastric cancer: an update of recommendations on definition, diagnosis, and treatment’: [Volume 2 - Issue C – 2023 2949-8198] (ESMO Gastrointestinal Oncology (2023) 2, (S2949819823000092), (10.1016/j.esmogo.2023.08.008))

  • T. E. Kroese
  • , R. van Hillegersberg
  • , P. S.N. van Rossum
  • , H. W.M. van Laarhoven*
  • *Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

Abstract

The authors regret that upon reviewing the final version, we identified an error in Figure 1, Page 4. The colour coding is incorrect and suggests a lack of consensus regarding bilobar liver metastases as oligometastatic disease, although consensus was in fact reached. • Current text: ≤ 3 unilobar liver metastases (consensus) ≤ 2 bilobar liver metastases (fair agreement).• Correction: ≤ 3 unilobar liver metastases (consensus) or ≤ 2 bilobar liver metastases (consensus).[Figure presented]The authors would like to apologise for any inconvenience caused.

Original languageEnglish
Article number100236
JournalESMO Gastrointestinal Oncology
Volume11
Early online date16 Sept 2025
DOIs
Publication statusPublished - Mar 2026

Fingerprint

Dive into the research topics of 'Corrigendum to ‘Oligometastatic disease in esophagogastric cancer: an update of recommendations on definition, diagnosis, and treatment’: [Volume 2 - Issue C – 2023 2949-8198] (ESMO Gastrointestinal Oncology (2023) 2, (S2949819823000092), (10.1016/j.esmogo.2023.08.008))'. Together they form a unique fingerprint.

Cite this